课题基金 / 基金详情

Development of a lyophilized intradermal/intranasal ricin vaccine

Development of a lyophilized intradermal/intranasal ricin vaccine
冻干皮内/鼻内蓖麻毒素疫苗的开发
批准号:
7446146
负责人:
ELLEN S VITETTA
金额:
$61.57万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-07-15 至 2011-06-30
关键词:
Acquired Immunodeficiency SyndromeActive ImmunizationAdjuvantAerosolsAmino AcidsAnatomyAntibodiesAntibody FormationAwardBioterrorismBloodBlood VesselsBotulinum ToxinsCastor OilCenters for Disease Control and Prevention (U.S.)ChicagoClassClinical TrialsCodeContractsCountryDevelopmentDiseaseDisruptionDoseDrug FormulationsEscherichia coliEuropeFoodFreezingFrightFundingGeneral PopulationGoalsGovernmentGrantHistopathologyHourHumanHuman ResourcesImmunizationImmunoglobulin AImmunoglobulin GImmunotoxinsIndividualInjectableInjection of therapeutic agentInternetIntoxicationIntramuscularLaboratoriesLanguageLearningLicensingLiteratureMalignant NeoplasmsMethodsMiddle EastMilitary PersonnelModelingMucous MembraneMusNamesNeedlesNumbersOralOryctolagus cuniculusPatientsPlant OilsPopulationPositioning AttributePowder dose formPreparationProceduresProductionProtocols documentationPublic HealthPublishingPurposeRecombinantsRecording of previous eventsReportingResearchResearch PersonnelRibosome InactivationRicinRicin A ChainRicin VaccineRicinus communisRouteSafetySiteStressStructureSurfaceSurvivorsSymptomsSyndromeSystemTemperatureTestingTimeTissuesToxic effectToxicologyToxinToxoidsTrainingTreatment ProtocolsUnited States National Institutes of HealthUpper Respiratory SystemVaccinatedVaccinationVaccinesWaterWater SupplyWorkWorld War IIaerosolizedanthrax lethal factorbasebeanbiothreatdayexperiencegraft vs host diseaseimmunogenicimmunogenicityimprovedinterestkillingsmaternal compound Wmutantnovelpilot trialprogramsuser-friendlyvaccine evaluationvolunteerwasting

项目摘要

项目成果

ELLEN S VITETTA的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Ricin is a highly lethal ribotoxin produced by castor beans. 50,000 tons of ricin are generated each year as a by product of castor oil production. Ricin has a long history of use in espionage and warfare and is classified by the CDC as a Class B biothreat. There is no approved vaccine. Ricin A chain (RTA) has two toxicities in humans: ribosome inactivation and vascular leak syndrome. We previously generated recombinant RTA mutants with single amino acid changes in both sites, and chose the best candidate vaccine based on high yield and stability. This vaccine (RiVax) was developed into a frozen, intramuscular formulation. Rivax is highly effective in protecting mice against ten LD50s of ricin. It was safe and immunogenic in both rabbits and humans. We developed a gavage challenge model for ricin and set up a BSL3 laboratory for aerosol challenges. During the course of our gavage challenge studies, we found that ricin was 1000-10,000 more toxic when delivered by gavage than the older literature had suggested. As a result of this finding, ricin represents a more serious threat to the food and water supply of our civilian population than we had realized previously. Thus there might be a greater need for this vaccine than previously appreciated. Hence, we now propose to develop: 1) a lyophilized formulation of RiVax that is stable at ambient temperatures or 4¿C; 2) an effective intradermal vaccination regimen that does not require needles and should be immunogenic at lower doses; 3) an intranasal formulation that will protect the mucosa against gavaged (and aerosolized) ricin. 4) Normal toxicology studies will be carried out on our best candidate formulations and regimens. Relevance of this research to public health (lav language): It is critical that both our military and civilian populations have access to an approved ricin vaccine that will protect them against both ingested and aerosolized ricin. This proposal represents a critical step in accomplishing this goal.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A novel vaccine to prevent HCV infection and hence liver cancer
  • 批准号:
    7943947
  • 项目类别:
  • 资助金额:
    $62.0万
  • 财政年份:
    2009
  • 负责人:
    ELLEN S VITETTA
  • 依托单位:
A novel vaccine to prevent HCV infection and hence liver cancer
  • 批准号:
    7852639
  • 项目类别:
  • 资助金额:
    $68.37万
  • 财政年份:
    2009
  • 负责人:
    ELLEN S VITETTA
  • 依托单位:
PHASE 1 STUDY OF SAFETY & IMMUNOGENICITY OF AN ALUM-FORMULATED RECOMBINANT RICIN
  • 批准号:
    7475286
  • 项目类别:
  • 资助金额:
    $32.17万
  • 财政年份:
    2007
  • 负责人:
    ELLEN S VITETTA
  • 依托单位:
PHASE 1 STUDY OF SAFETY & IMMUNOGENICITY OF AN ALUM-FORMULATED RECOMBINANT RICIN
  • 批准号:
    7213715
  • 项目类别:
  • 资助金额:
    $30.77万
  • 财政年份:
    2007
  • 负责人:
    ELLEN S VITETTA
  • 依托单位:
海外基金